Levetiracetam
Product Images NDC 81646-116

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 81646-116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pinnacle Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Levetiracetam Solution 1)

Chemical structure of Levetiracetam, showing its molecular arrangement with a pyrrolidone ring, an ethyl group, and an amide side chain. The diagram highlights key atoms and bonds of the active ingredient.*

FDA Label Image

Figure 1 (Levetiracetam Solution 2)

A bar chart showing the percentage of patients responding to treatments: 7.4% for placebo (N=95), 37.1% for Levetiracetam 1000 mg/day (N=97), and 39.6% for Levetiracetam 3000 mg/day (N=101). The y-axis represents the percentage of patients from 0% to 45%. Each bar is labeled with the exact percentage.*

FDA Label Image

Figure 2 (Levetiracetam Solution 3)

A bar chart showing the percentage of patients in three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, with values approximately 6.3% for Placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day. Each bar is labeled with its corresponding percentage and sample size (N).*

FDA Label Image

Figure 3 (Levetiracetam Solution 4)

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The Placebo group shows 14.4% of patients, while the Levetiracetam group shows 39.4% of patients. The vertical axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Figure 4 (Levetiracetam Solution 5)

Bar chart comparing the percentage of patients for Placebo (19.6%, N=97) and Levetiracetam (44.6%, N=101). The vertical axis is labeled '% of Patients' ranging up to 45%, with Levetiracetam showing a higher percentage than Placebo.*

FDA Label Image

Figure 5 (Levetiracetam Solution 6)

A bar chart comparing the percentage of patients between placebo (N=51) and Levetiracetam (N=58) groups. The Levetiracetam group shows a higher percentage of patients (43.1%) versus the placebo group (19.6%), with a note indicating statistical significance versus placebo.*

FDA Label Image

Figure 6 (Levetiracetam Solution 7)

A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis represents the percentage of patients, with the placebo group at 45.2% and the Levetiracetam group at 72.2%, indicating a higher percentage in the Levetiracetam group.*

FDA Label Image

Cup Label (Levetiracetam Solution 8)

Levetiracetam 500 mg/5 mL oral solution label displays drug name, strength, dosage form, and 'Rx only'. Includes barcode, expiration date of 04/09/2021, lot number 123456, manufacturer PAI, manufacturer lot C4F7, and distribution by Pinnacle Pharma.*

FDA Label Image

Box Label (Levetiracetam Solution 9)

Label for Levetiracetam oral solution 500 mg/5 mL by Pinnacle Pharma LLC. The label indicates storage instructions at controlled room temperature and package quantity of 72 cups of 5 mL each. It includes a barcode, QR code, RX designation, and batch details placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.